StockData
Johnson & Johnson logo

Johnson & Johnson

JNJNYSEPharmaceutical PreparationsFiscal year ends January 3
Financials through Q2 FY2026, quarter ended Jun 28, 2026Last filing: 10-Q on Oct 21, 2026Score 12/3042% above fair value
$270.56−2.64 (-0.97%)

Close on Nov 2, 2026Market cap $652.02BP/E 31.4Yield 1.90%

Johnson & Johnson TECVAYLI (teclistamab) by Year

TECVAYLI (teclistamab) — International operational growth YoY (%) (%)

QuarterlyAnnual

Johnson & Johnson TECVAYLI (teclistamab): 70.4% in FY2025.

Latest, FY2025
70.4%
Period ended Dec 28, 2025
Change on a year earlier
–
History
1 years
Since FY2025
Sources
1
Form 8-K (a2025q4exhibit991.htm, filed 2026-01-21)

Where the FY2025 figure comes from

“|| Intl | 226 | 131 | 72.8 | 70.4 | 2.4”

Source: Form 8-K (a2025q4exhibit991.htm, filed 2026-01-21) ↗

Reported in Form 8-K EX-99.2 Segment Sales Schedule.

Annual history

Hover a value to see the sentence it was read from; calculated values show their formula

PeriodEndedTECVAYLI (teclistamab) — International operational growth YoY (%) (%)Year on yearSource
FY2025Dec 28, 202570.4%–Form 8-K (a2025q4exhibit991.htm, filed 2026-01-21) ↗

Cite this data

StockData. (2026). Johnson & Johnson TECVAYLI (teclistamab) (%), annual FY2025–FY2025 [Data set]. Compiled from Johnson & Johnson SEC filings and investor materials. https://stockdatahq.com/stocks/jnj/kpis/drug-tecvayli-intl-ops-yoy

See every metric in the Johnson & Johnson KPI table. Data updated Oct 25, 2026.